Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ.

Blood. 2007 Sep 15;110(6):2166-72. Epub 2007 May 29.

2.

Sickle cell anemia and vascular dysfunction: the nitric oxide connection.

Akinsheye I, Klings ES.

J Cell Physiol. 2010 Sep;224(3):620-5. doi: 10.1002/jcp.22195. Review.

PMID:
20578237
3.

Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis.

Deonikar P, Kavdia M.

J Appl Physiol (1985). 2012 Apr;112(8):1383-92. doi: 10.1152/japplphysiol.01173.2011. Epub 2012 Jan 5.

4.

Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.

Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT.

Blood. 2007 Apr 1;109(7):3088-98. Erratum in: Blood. 2008 Feb 15;111(4):1772.

5.

Molecular link between intravascular hemolysis and vascular occlusion in sickle cell disease.

Zhou Z, Yee DL, Guchhait P.

Curr Vasc Pharmacol. 2012 Nov;10(6):756-61. Review.

PMID:
22272904
6.

Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Kato GJ, Gladwin MT.

JAMA. 2008 Dec 10;300(22):2638-46. doi: 10.1001/jama.2008.598. Review.

7.

Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.

Gudmundsdóttir IJ, McRobbie SJ, Robinson SD, Newby DE, Megson IL.

Biochem Biophys Res Commun. 2005 Nov 11;337(1):382-5.

PMID:
16185664
8.

Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.

Atz AM, Wessel DL.

Anesthesiology. 1999 Jul;91(1):307-10. No abstract available.

PMID:
10422958
9.

Pulmonary hypertension in sickle cell disease: relevance to children.

Kato GJ, Onyekwere OC, Gladwin MT.

Pediatr Hematol Oncol. 2007 Apr-May;24(3):159-70. Review.

10.

Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.

Lewis GD, Semigran MJ.

Curr Heart Fail Rep. 2004 Dec;1(4):183-9. Review.

PMID:
16036043
11.

Revisiting the hyperhemolysis paradigm.

Gladwin MT.

Blood. 2015 Aug 6;126(6):695-6. doi: 10.1182/blood-2015-06-649491.

12.
13.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
14.

Cardiovascular data on sildenafil citrate: introduction.

Zusman RM.

Am J Cardiol. 1999 Mar 4;83(5A):1C-2C. No abstract available. Erratum in: Am J Cardiol 1999 Jul 15;84(2):244.

PMID:
10078536
15.

Sickle cell disease vasculopathy: a state of nitric oxide resistance.

Wood KC, Hsu LL, Gladwin MT.

Free Radic Biol Med. 2008 Apr 15;44(8):1506-28. doi: 10.1016/j.freeradbiomed.2008.01.008. Epub 2008 Jan 26. Review.

PMID:
18261470
16.

[Pathophysiological consequences of hemolysis. Role of cell-free hemoglobin].

Misztal T, Tomasiak M.

Postepy Hig Med Dosw (Online). 2011 Sep 28;65:627-39. Review. Polish.

17.

Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease.

Taylor JG 6th, Ackah D, Cobb C, Orr N, Percy MJ, Sachdev V, Machado R, Castro O, Kato GJ, Chanock SJ, Gladwin MT.

Am J Hematol. 2008 Jan;83(1):6-14.

18.

Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT.

Am J Hematol. 2006 Jul;81(7):503-10.

19.

Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis.

Musicki B, Bivalacqua TJ, Champion HC, Burnett AL.

J Sex Med. 2014 Feb;11(2):424-30. doi: 10.1111/jsm.12391. Epub 2013 Nov 20.

20.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Hoeper MM, Welte T.

N Engl J Med. 2006 Mar 9;354(10):1091-3; author reply 1091-3. No abstract available.

Supplemental Content

Support Center